Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy.

Chen X, Nakayama H, Zhang X, Ai X, Harris DM, Tang M, Zhang H, Szeto C, Stockbower K, Berretta RM, Eckhart AD, Koch WJ, Molkentin JD, Houser SR.

J Mol Cell Cardiol. 2011 Mar;50(3):460-70. doi: 10.1016/j.yjmcc.2010.11.012. Epub 2010 Nov 25.

2.

Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling.

Gao H, Wang F, Wang W, Makarewich CA, Zhang H, Kubo H, Berretta RM, Barr LA, Molkentin JD, Houser SR.

J Mol Cell Cardiol. 2012 Nov;53(5):657-67. doi: 10.1016/j.yjmcc.2012.08.005. Epub 2012 Aug 21.

3.

CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes.

MacDonnell SM, Weisser-Thomas J, Kubo H, Hanscome M, Liu Q, Jaleel N, Berretta R, Chen X, Brown JH, Sabri AK, Molkentin JD, Houser SR.

Circ Res. 2009 Aug 14;105(4):316-25. doi: 10.1161/CIRCRESAHA.109.194035. Epub 2009 Jul 16.

4.

Ca2+ influx-induced sarcoplasmic reticulum Ca2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes.

Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, Berretta R, Potts ST, Marsh JD, Houser SR.

Circ Res. 2005 Nov 11;97(10):1009-17. Epub 2005 Oct 6.

5.

Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.

Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S.

Circ Res. 2008 Oct 10;103(8):891-9. doi: 10.1161/CIRCRESAHA.108.175141. Epub 2008 Sep 5.

6.

Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.

Ding W, Dong M, Deng J, Yan D, Liu Y, Xu T, Liu J.

Am J Physiol Heart Circ Physiol. 2014 Sep 1;307(5):H792-802. doi: 10.1152/ajpheart.00017.2014. Epub 2014 Jul 11.

PMID:
25015961
7.

Caveolae-specific activation loop between CaMKII and L-type Ca2+ channel aggravates cardiac hypertrophy in α1-adrenergic stimulation.

Tonegawa K, Otsuka W, Kumagai S, Matsunami S, Hayamizu N, Tanaka S, Moriwaki K, Obana M, Maeda M, Asahi M, Kiyonari H, Fujio Y, Nakayama H.

Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H501-H514. doi: 10.1152/ajpheart.00601.2016. Epub 2016 Dec 30.

PMID:
28039202
8.

Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.

Barr LA, Makarewich CA, Berretta RM, Gao H, Troupes CD, Woitek F, Recchia F, Kubo H, Force T, Houser SR.

Clin Transl Sci. 2014 Oct;7(5):360-7. doi: 10.1111/cts.12173. Epub 2014 Jun 16.

9.

Ca2+ influx through T- and L-type Ca2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes.

Jaleel N, Nakayama H, Chen X, Kubo H, MacDonnell S, Zhang H, Berretta R, Robbins J, Cribbs L, Molkentin JD, Houser SR.

Circ Res. 2008 Nov 7;103(10):1109-19. doi: 10.1161/CIRCRESAHA.108.185611. Epub 2008 Oct 2.

10.

{beta}1-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways.

Wang W, Zhang H, Gao H, Kubo H, Berretta RM, Chen X, Houser SR.

Am J Physiol Heart Circ Physiol. 2010 Aug;299(2):H322-31. doi: 10.1152/ajpheart.00392.2010. Epub 2010 May 21.

11.

Sarcoplasmic reticulum adenosine triphosphatase overexpression in the L-type Ca2+ channel mouse results in cardiomyopathy and Ca2+ -induced arrhythmogenesis.

Rubio M, Bodi I, Fuller-Bicer GA, Hahn HS, Periasamy M, Schwartz A.

J Cardiovasc Pharmacol Ther. 2005 Dec;10(4):235-49.

PMID:
16382260
12.

Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.

Dai H, Jia G, Liu X, Liu Z, Wang H.

Environ Toxicol Pharmacol. 2014 Jul;38(1):263-71. doi: 10.1016/j.etap.2014.05.008. Epub 2014 Jun 13.

PMID:
24975447
13.

Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model.

van Oort RJ, Respress JL, Li N, Reynolds C, De Almeida AC, Skapura DG, De Windt LJ, Wehrens XH.

Hypertension. 2010 Apr;55(4):932-8. doi: 10.1161/HYPERTENSIONAHA.109.146449. Epub 2010 Feb 15.

14.

Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.

Kato T, Sano M, Miyoshi S, Sato T, Hakuno D, Ishida H, Kinoshita-Nakazawa H, Fukuda K, Ogawa S.

Circ Res. 2000 Nov 10;87(10):937-45.

15.

Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload.

Ago T, Yang Y, Zhai P, Sadoshima J.

J Cardiovasc Transl Res. 2010 Aug;3(4):304-13. doi: 10.1007/s12265-010-9182-x. Epub 2010 May 1.

16.

Effects of thapsigargin and phenylephrine on calcineurin and protein kinase C signaling functions in cardiac myocytes.

Prasad AM, Inesi G.

Am J Physiol Cell Physiol. 2009 May;296(5):C992-C1002. doi: 10.1152/ajpcell.00594.2008. Epub 2009 Feb 25.

17.

Effects on recovery during acidosis in cardiac myocytes overexpressing CaMKII.

Sag CM, Dybkova N, Neef S, Maier LS.

J Mol Cell Cardiol. 2007 Dec;43(6):696-709. Epub 2007 Oct 22.

PMID:
17950750
18.

Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.

Liu W, Deng J, Ding W, Wang G, Shen Y, Zheng J, Zhang X, Luo Y, Lv C, Wang Y, Chen L, Yan D, Boudreau RL, Song LS, Liu J.

Circ Heart Fail. 2017 Jun;10(6). pii: e003960. doi: 10.1161/CIRCHEARTFAILURE.117.003960. Retraction in: Circ Heart Fail. 2017 Nov;10 (11):.

PMID:
28611128
19.

Effect of distinct sources of Ca(2+) on cardiac hypertrophy in cardiomyocytes.

Xu H, Zhang Y, Sun J, Wei J, Sun L, Zhang J.

Exp Biol Med (Maywood). 2012 Mar;237(3):271-8. doi: 10.1258/ebm.2011.011273. Epub 2012 Feb 16.

PMID:
22345300
20.

Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.

Bisserier M, Berthouze-Duquesnes M, Breckler M, Tortosa F, Fazal L, de Régibus A, Laurent AC, Varin A, Lucas A, Branchereau M, Marck P, Schickel JN, Deloménie C, Cazorla O, Soulas-Sprauel P, Crozatier B, Morel E, Heymes C, Lezoualc'h F.

Circulation. 2015 Jan 27;131(4):390-400; discussion 400. doi: 10.1161/CIRCULATIONAHA.114.010686. Epub 2014 Nov 4.

Supplemental Content

Support Center